Effect of natural analogues of trans-resveratrol on cytochromes P4501A2 and 2E1 catalytic activities

Xenobiotica

Volumn 36, Issue 4, 2006, Pages 269-285

  Mikstacka, R ^a   Rimando, A M ^b   Szalaty, K ^a   Stasik, K ^a   Baer Dubowska, W ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b NATURAL PRODUCTS UTILIZATION RESEARCH UNIT   (United States)

Author keywords

Chemoprevention; CYP1A2; CYP2E1; Stilbene derivatives; Trans resveratrol

Indexed keywords

3,4' DIHYDROXY 5 METHOXYSTILBENE; 3,5 DIHYDROXY 4' METHOXYSTILBENE; 4 NITROPHENOL; 4 NITROPHENOL HYDROXYLASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; ETHOXYRESORUFIN DEETHYLASE; FUNCTIONAL GROUP; HYDROXYL GROUP; METHOXY GROUP; OXYGENASE; PICEATANNOL; PTEROSTILBENE; RESVERATROL; RESVERATROL DERIVATIVE; RESVERATROL TRIMETHYL ETHER; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHEMOPROPHYLAXIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IC 50; IN VITRO STUDY; INHIBITION KINETICS; METHYLATION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; CATALYTIC DOMAIN; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; INHIBITORY CONCENTRATION 50; KINETICS; LIVER; MICE; STILBENES;

ANIMALIA;

EID: 33646767096     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500485057     Document Type: Article

References (54)

1. Baer-Dubowska W, Szaefer H, Krajka-Kuźniak V. 1998. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobiotica 28:735-743.
2. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT. 1985. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochemistry and Pharmacology 34:3337-3345.
3. Chang TKH, Chen J, Lee WBK. 2001. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: Evidence for mechanism-based inactivation of CYP1A2. Journal of Pharmacology and Experimental Therapy 299:874-882.
4. Chang TKH, Lee WBK, Ko HH. 2000. Trans-resveratrol modulates the catalytic activity and m-RNA expression of the procarcinogen-activating human cytochrome P450 1B1. Canadian Journal of Physiology and Pharmacology 78:874-881.
5. Chang TKH, Yeung RKY. 2001. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalysed by human recombinant CYP3A4 and CYP3A5. Canadian Journal of Physiology and Pharmacology 79:220-226.
6. Chun YJ, Kim MY, Guengerich FP. 1999. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochemical and Biophysical Research Communications 268:20-24.
7. Chun YJ, Ryu SY, Jeong TC, Kim MY. 2001. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metabolism and Disposition 29:389-393.
8. DiGiovanni J. 1990. Inhibition of chemical carcinogenesis. In: Cooper CS, Grover PL, editors. Handbook of experimental pharmacology. Berlin: Springer. pp 159-223.
9. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. 1995. Role of cytochrome P4501A2 in chemical carcinogenesis: Implication for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274.
10. Fremont L. 2000. Biological effects of resveratrol. Life Sciences 66:663-673.
11. Gerhäuser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauft J, Liu G-Y, Sitthimonchai S, Frank N. 2003. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutation Research 523-524:163-172.
12. Gescher AJ, Steward WP. 2003. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiology and Biomarkers 12:953-957.
13. Guengerich FP. 1994. Analysis and characterization of enzymes. In: Hayes AW, editor. Principles and methods of toxicology. New York, NY: Raven. pp 1259-1313.
14. Guengerich FP, Chun Y-J, Kim D, Gillam EMJ, Shimada T. 2003. Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies. Mutation Research 523-524:173-182.
15. Hargreaves MB, Jones BC, Smith DA, Gescher A. 1994. Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metabolism and Disposition 22:806-810.
16. Ignatowicz E, Baer-Dubowska W. 2001. Resveratrol, a natural chemopreventive agent against degenerative diseases. Polish Journal of Pharmacology 53:557-569.
17. Jang DS, Kang BS, Ryu SY, Chang IM, Min KR, Kim Y. 1999. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochemistry and Pharmacology 57:705-712.
18. Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lang NP. 1992. Polymorphisms for aromatic amine metabolism in humans: Relevance for human carcinogenesis. Environmental Health Perspectives 98:69-74.
19. Kerem Z, Regev-Shoshani G, Flaishman MA, Sivan L. 2003. Resveratrol and two monomethylated stilbenes from Israeli Rumex bucephalophorus and their antioxidant potential. Journal of Natural Products 66:1270-1272.
20. Kim S, Ko H, Park JE, Jung S, Lee SK, Chun YJ. 2002. Design, synthesis and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. Journal of Medicinal Chemistry 45:160-164.
21. Ko SK, Lee CR, Lee HS, Kim H, Baek KH, Tokuoka K, Chung SH. 2003. Inhibitory effects of stilbene derivatives from Rheum undulatum on cyclooxygenase activity. Saengyak Hakhoechi 34:25-27.
22. Kobayashi K, Urishima K, Shimada N, Chiba K. 2002. Substrate specificity for rat cytochrome P450 (CYP) isoforms: Screening with cDNA-expressed systems of the rat. Biochemistry and Pharmacology 63:889-896.
23. Koop DR. 1986. Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a. Molecular Pharmacology 29:399-404.
24. Krajka-Kuźniak V, Baer-Dubowska W. 2003. The effects of tannic acid on cytochrome P450 and phase II enzyme in mouse liver and kidney. Toxicology Letters 143:209-216.
25. Lang NP, Butler MA, Mussengill J, Lawson M, Stotts RC, Hauer-Jensen M, Kadlubar FF. 1994. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiology and Biomarkers 3:675-682.
26. Latruffe N, Delmas D, Jannin B, Cherkaoui-Malki M, Passilly-Degrace P, Berlot JP. 2002. Molecular analysis on the chemopreventive properties of resveratrol a plant polyphenol microcomponent. International Journal of Molecular Medicine 10:755-760.
27. Le Marchand L, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN, Seifried A, Custer LJ, Chang W, Lum-Jones A, Donlon T. 2001. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiology and Biomarkers 10:1259-1266.
28. Lee SH, Ryu SY, Kim HB, Kim MY, Chun YJ. 2002. Induction of apoptosis by 3,4′-dimethoxy-5-hydroxystilbene in human promyeloid leukemic HL-60 cells. Planta Medica 68:123-127.
29. Lewis DFV, Lake BG, Dickins M. 2004. Quantitative structure-activity relationships within a homologous series of 7-alkoxyresorufins exhibiting activity towards CYP1A and CYP2B enzymes: Molecular modeling studies on key members of the resorufin series with CYP2C5-derived models of human CYP1A1, CYP1A2, CYP2B6 and CYP3A4. Xenobiotica 34:501-513.
30. Likhitwitayawuid K, Sawasdee K, Kirtikara K. 2002. Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracena loureiri. Planta Medica 68:841-843.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193:230-265.
32. Matsuda H, Tewtrakul S, Morikawa T, Yoshikawa M. 2004. Anti-allergic activity of stilbenes from Korean rhubarb (Rheum undulatum L.): Structure requirements for inhibition of antigen-induced degranulation and their effects on the release of TNF-α and IL-4 in RBL-2H3 cells. Bioorganic and Medicinal Chemistry 12:4871-4876.
33. Matsuoka A, Takeshita K, Furuta A, Ozaki M, Fukuhara K, Miyata N. 2002. The 4′-hydroxy group is responsible for the in vitro cytogenetic activity of resveratrol. Mutation Research 521:29-35.
34. Mikstacka R, Gnojkowski J, Baer-Dubowska W. 2002. Effect of natural phenols on the catalytic activity of cytochrome P450 2E1. Acta Biochimica Polonica 49:917-925.
35. Pettit GR, Singh SB, Schmidt JM, Niven ML, Hamel E, Lin CH. 1988. Isolation, structure, synthesis, and antimitotic properties of combrestatins B-3 and B-4 from Combretum caffrum. Journal of Natural Products 51:517-527.
36. Piver B, Berthou F, Dreano Y, Lucas D. 2001. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicology Letters 125:83-91.
37. Piver B, Fer M, Vitrac X, Merillon J-M, Dreano Y, Berthou F, Lucas D. 2004. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochemistry and Pharmacology 68:773-782.
38. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA, Burke MD. 2002. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. British Journal of Cancer 86:774-778.
39. Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z. 2003. Glycosylation of resveratrol protects it from enzymatic oxidation. Biochemistry Journal 374:157-163.
40. Regev-Shoshani G, Shoseyov O, Kerem Z. 2004. Influence of lipophilicity on the interactions of hydroxyl stilbenes with cytochrome P450 3A4. Biochemical and Biophysical Research Communications 323:668-673.
41. Reinke LA, Moyer MJ. 1985. p-Nitrophenol hydroxylation - a microsomal oxidation which is highly inducible by ethanol. Drug Metabolism and Disposition 13:548-552.
42. Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM, Duke OD. 2002. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. Journal of Agriculture and Food Chemistry 50:3453-3457.
43. Rimando AM, Pezzuto JM, Farnsworth NR, Santisuk T, Reutraul V. 1994. Revision of the NMR assignments of pterostilbene and of dihydrodehydroconiferyl alcohol: Cytotoxic constituents from Anogeissus acuminata. Natural Product Letters 4:267-272.
44. Ryu SY, Choi SU, Lee CO, Lee SH, Ahn JW, Zee OP. 1994. Antitumor activity of some phenolic components in plants. Archives in Pharmacology Research 17:42-44.
45. Sale S, Verschoyle RD, Boocock D, Jones DJL, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP, Gescher AJ. 2004. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans-3,4,5,4′- tetramethoxystilbene. British Journal of Cancer 90:736-744.
46. Smith DA, Abel SM, Hyland R, Jones BC. 1998a. Human cytochrome P450s: Selectivity and measurement in vivo. Xenobiotica 28:1095-1128.
47. Smith G, Stubbins MJ, Harries W, Wolf CR. 1998b. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28:1129-1165.
48. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP. 2004. Genetic variation in eleven phase I drug metabolizm genes in an ethnically diverse population. Pharmacogenomics 5:895-931.
49. Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E, Vannini V. 2001. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. Journal of Biological Chemistry 276:22586-22594.
50. Sumner SC, Fennell TR, Moore TA, Chanas B, Gonzales F, Ghanayem BI. 2005. Role of cytochrome P4502E1 in the metabolism of acrylamide and acrylonitrile in mice. Chemical Research in Toxicology 12:1110-1116.
51. Surh YJ. 1999. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutation Research 428:305-327.
52. Szaefer H, Cichocki M, Brauze D, Baer-Dubowska W. 2004. Alteration in phase I and II enzyme activities and polycyclic aromatic hydrocarbons-DNA adduct formation by plant phenolics in mouse epidermis. Nutrition and Cancer 48:70-77.
53. Yin Q, Shi Y-M, Liu H-M, Li C-B, Zhang W-Q. 2002. (E)-3,5,4′- Trimethoxystilbene. Acta Crystallographica 58:1180-1181.
54. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG, Van RB. 2002. Human, rat, and mouse metabolism of resveratrol. Pharmacology Research 19:1907-1914.